Vážení členovia,
informujeme vás o spôsobe práce EMA počas najbližších týždňov:
Dear Industry Stakeholders,
In view of the rapidly changing situation in the context of the COVID-19 pandemic, I would like to inform you that, as of Monday, 16 March 2020, the vast majority of EMA staff members is working remotely. This measure is in line with the steps taken by the European Commission and aims to support the Dutch Government’s efforts to slow down the spread of COVID-19. Despite the reduction of the physical presence in the Agency’s premises to a minimum, EMA’s operations will be maintained. The new measure is currently planned to last until the end of April 2020 but may be further extended if the situation requires.
A limited number of staff will be present at the office to ensure continuity of critical business processes which have to be performed on site.
This measure follows our decision from last week to hold all meetings of the EMA Management Board, scientific committees and working parties, as well as stakeholder events virtually until the end of April 2020.
Our plans are being continually reviewed and we will update you as the situation develops.
.Thank you for your continued collaboration and for forwarding this information to your respective (affiliated) Members, as appropriate,
Once again, please not hesitate to contact me should you have any questions.
Yours sincerely,
Marie-Hélène
Dr. Marie-Hélène PinheiroIndustry Corporate Liaison
Stakeholder and Communication Division
European Medicines AgencyDomenico Scarlattilaan 6 | 1083 HS Amsterdam | The NetherlandsTelephone +31 (0)88 781 8620marie-helene.pinheiro@ema.europa.eu | www.ema.europa.eu | For directions, see How to find usFollow us: This message and any attachment contain information which may be confidential or otherwise protected from disclosure. It is intended for the addressee(s) only and should not be relied upon as legal advice unless it is otherwise stated. If you are not the intended recipient(s) (or authorised by an addressee who received this message), access to this e-mail, or any disclosure or copying of its contents, or any action taken (or not taken) in reliance on it is unauthorised and may be unlawful. If you have received this e-mail in error, please inform the sender immediately.